<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1005">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347152</url>
  </required_header>
  <id_info>
    <org_study_id>10399</org_study_id>
    <nct_id>NCT00347152</nct_id>
  </id_info>
  <brief_title>Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability</brief_title>
  <official_title>Overnight Versus Progressive Conversion of Multiple Daily Dose Enteric-Coated Divalproex to Once-Daily Divalproex Extended Release: Which Strategy is Better Tolerated by Patients With Intellectual Disabilities?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is any difference in side effects
      experienced by individuals with intellectual disorders taking Depakote DR (immediate release
      form) when they are switched to the extended release form (ER) overnight versus when they
      switch more gradually over a week.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Considering that there are potential advantages to once-daily depakote extended release in
      terms of decreased side effects, decreased medication errors and patient compliance, there
      is a need to determine the best method of conversion from multiple-daily dose delayed
      release depakote to once-daily for subjects with epilepsy bipolar disorder or behavior
      disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>direct observation of side effects by staff and investigator, side effect ratings using the MOSES side effect rating scale post-switch. (Multidimensional observational scale for elderly subjects)</measure>
    <time_frame>Baseline to day +8</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>seizures observed, compared with prior rate of seizures;maintenance of clinical response using the Clinical Global Impressions Scale-improvement subscale;</measure>
    <time_frame>Baseline to day + 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total valproic acid serum levels (trough of pre-dose measurements)</measure>
    <time_frame>Prior to conversion, 1 week post conversion</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in blood work, including CBC, platelet counts, LFT, serum chemistry panel</measure>
    <time_frame>Prior to and one week post conversion</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Slow Progressive Divalproex DR to Divalproex ER switch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate, Progressive Divalproex DR to Divalproex ER switch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex</intervention_name>
    <description>Divalproex, 8-20% taper</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Depakote</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex</intervention_name>
    <description>Divalproex, 8-20% taper</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Depakote</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients currently taking divalproex direct release for any seizure and/or behavior
             disorder

          -  patients with intellectual disability

          -  other medications for co-morbid disease are permitted, provided no plans for changes
             in medication used for the treatment of the disorder are expected

        Exclusion Criteria:

          -  patients with a recent history of status epilepticus in the past 6 months

          -  seizures in the past 3 months

          -  patients with acute illness requiring changes in concurrent drugs

          -  patients unwilling to change from their present direct release divalproex to
             divalproex extended release

          -  patients that do not have a reliable caregiver

          -  patients with lack of verbal expressive speech
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Hellings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <lastchanged_date>September 10, 2008</lastchanged_date>
  <firstreceived_date>June 30, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Jessica Hellings, MD</name_title>
    <organization>University of Kansas Medical Center</organization>
  </responsible_party>
  <keyword>Intellectual disabilities</keyword>
  <keyword>development disabilities</keyword>
  <keyword>behavior disorders</keyword>
  <keyword>stable epilepsy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Intellectual Disability</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
